Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Trial Profile

Topical Infliximab in Autoimmune Eyes With Keratoprosthesis

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Pemphigoid; Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to withdrawn prior to enrolment as No patients met eligibility criteria.
    • 03 Apr 2017 Planned End Date changed from 1 Mar 2017 to 3 Apr 2017.
    • 02 Nov 2014 Status changed from not yet recruiting to recruiting as reported by record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top